Dying patients wait in vain after Trump-era easing of drug law


6 April 2021 - Companies hold back experimental medications from those who want them most. They say they have good reasons, but not everyone agrees.

Lisa Stockman-Mauriello is dying. She has one last ambition: to live long enough to see her three sons graduate this year — from middle school, high school and college. She and her doctor believe she needs a new experimental drug to hold on. She’s unlikely to get it.

Read Bloomberg article

Michael Wonder

Posted by:

Michael Wonder

Posted in:

Medicine , US , Regulation , Market access